Neovacs (STU:0LW) Asset Impairment Charge : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Neovacs Asset Impairment Charge?

Neovacs's Asset Impairment Charge for the six months ended in Dec. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Neovacs Asset Impairment Charge Historical Data

The historical data trend for Neovacs's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovacs Asset Impairment Charge Chart

Neovacs Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

Neovacs Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Neovacs Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Neovacs Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Neovacs's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Neovacs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neovacs SA (STU:0LW) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

0W8U:UK ALNEV:France 0LW:Germany

Address

3-5, Impasse Reille, Paris, FRA, 75014

Website

http://www.neovacs.fr

Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Neovacs Headlines

No Headlines